IP Library Granted Patent US 8,106,078
Granted Patent B2
US 8,106,078 · App. 12/850,026 · Granted Jan 31, 2012

Human protein tyrosine phosphatase inhibitors and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,106,078
App. No.
12/850,026
Granted
Jan 31, 2012
Kind
B2
Abstract

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

Claims (74)

1. A method for regulating angiogenesis in a human, comprising administering to a human an effective amount of a compound having the formula:

wherein R is a substituted or unsubstituted thiazolyl unit having the formula:

R 2 and R 3 are each independently chosen from:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

iii) substituted or unsubstituted phenyl;

iv) substituted or unsubstituted heteroaryl; or

R 2 and R 3 can be taken together to form a saturated or unsaturated ring having from 5 to 7 atoms;

said substitutions are independently chosen from one or more C 1 -C 6 linear, C 3 -C 6 branched, or C 1 -C 6 cyclic alkyl, —N(R 11 ) 2 , —OR 11 , halogen, hydroxyl, or cyano units; each R 11 is independently hydrogen, C 11 linear or C 3 -C 4 branched alkyl;

R 4 is a unit chosen from:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

iii) substituted or unsubstituted phenyl; or

iv) substituted or unsubstituted heteroaryl;

said substitutions are independently chosen from one or more C 1 -C 6 linear, C 3 -C 6 branched, or C 1 -C 6 cyclic alkyl, —N(R 11 ) 2 , —OR 11 , halogen, hydroxyl, or cyano units; each R 11 is independently hydrogen, C 1 -C 4 linear or C 3 -C 4 branched alkyl;

Z is a unit having the formula:

R 1 is chosen from:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

iii) substituted or unsubstituted aryl;

iv) substituted or unsubstituted heterocyclic rings; or

v) substituted or unsubstituted heteroaryl rings;

said substitutions are independently chosen from one or more halogen, C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl, —OR 11 , —CN, —N(R 11 ) 2 , —CO 2 R 11 , —C(O)N(R 11 ) 2 , —NR 11 C(O)R 11 , —NO 2 , —SO 2 R 11 , phenyl, benzyl; when R 1 is substituted by phenyl or benzyl, said phenyl or benzyl can be substituted by halogen, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, —CO 2 R 11 and —NHCOR 16 ; each R 11 is independently hydrogen; substituted or unsubstituted C 1 -C 4 linear, branched, cyclic alkyl, alkenyl, or alkynyl; substituted or unsubstituted phenyl or benzyl; or two R 11 units can be taken together to form a ring comprising from 3-7 atoms; each R 16 is independently hydrogen, methyl, or ethyl; L is a linking unit chosen from:

i) —C(O)NH[C(R 5a R 5b )] w —;

ii) —C(O)[C(R 6a R 6b )]—;

iii) —C(O)[C(R 7a R 7b )] y C(O)—;

iv) —SO 2 [C(R 8a R 8b )] z —;

R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8a , and R 8b are each independently:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 4 linear or C 3 -C 4 branched alkyl;

iii) substituted or unsubstituted aryl;

iv) substituted or unsubstituted heterocyclic rings; or

v) substituted or unsubstituted heteroaryl rings;

the index n is 0 or 1; the indices w and z are each independently from 0 to 4 and the indices x and y are each independently from 1 to 4;

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , wherein the compounds are salts comprising anions chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate.

3. The method according to claim 1 , wherein the compounds are salts comprising cations chosen from ammonium, sodium, lithium, potassium, calcium, magnesium, and bismuth.

4. The method according to claim 1 , wherein R has the formula:

5. The method according to claim 4 , wherein R 2 and R 3 are each hydrogen or substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl.

6. The method according to claim 4 , wherein R 2 is chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl; and R 3 is hydrogen.

7. The method according to claim 4 , wherein R 2 is substituted or unsubstituted phenyl and R 3 is hydrogen.

8. The method according to claim 4 , wherein R 2 is substituted or unsubstituted heteroaryl and R 3 is hydrogen.

9. The method according to claim 8 , wherein R 2 is a heteroaryl unit chosen from 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, and [1,3,4]thiadiazol-2-yl.

10. The method according to claim 9 , wherein R 2 is thiophen-2-yl or thiophen-3-yl.

11. The method according to claim 1 , wherein R has the formula:

12. The method according to claim 11 , wherein R 4 is hydrogen or substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl.

13. The method according to claim 12 , wherein R 4 is chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl; and R 3 is hydrogen.

14. The method according to claim 11 , wherein R 4 is substituted or unsubstituted phenyl and R 3 is hydrogen.

15. The method according to claim 11 , wherein R 4 is substituted or unsubstituted heteroaryl.

16. The method according to claim 15 , wherein R 4 is a heteroaryl unit chosen from 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, and [1,3,4]thiadiazol-2-yl.

17. The method according to claim 16 , wherein R 4 is thiophene-2-yl or thiophene-3-yl.

18. The method according to claim 1 , wherein L has the formula:

—C(O)[C(R 6a R 6b )] x —

R 6a is hydrogen, substituted or unsubstituted phenyl, or substituted or unsubstituted heteroaryl; the index x is 1 or 2.

19. The method according to claim 18 , wherein R 1 is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, and 3,5-dimethoxyphenyl.

20. The method according to claim 1 , wherein L has the formula —C(O)CH 2 —.

21. The method according to claim 1 , wherein L has the formula —C(O)CH 2 CH 2 —.

22. The method according to claim 1 , wherein R 1 is a substituted or unsubstituted heteroaryl unit, said substitutions chosen from:

i) C 1 -C 6 linear, branched, and cyclic alkyl;

ii) substituted or unsubstituted phenyl and benzyl;

iii) substituted of unsubstituted heteroaryl;

iv) —C(O)R 9 ; or

v) —NHC(O)R 9 ;

R 9 is C 1 -C 6 linear and C 3 -C 6 branched alkyl; C 1 -C 6 linear and C 3 -C 6 branched alkoxy; or —NHCH 2 C(O)R 10 ; R 10 is chosen from hydrogen, methyl, ethyl, and tert-butyl.

23. The method according to claim 22 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by an alkyl unit chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl.

24. The method according to claim 22 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by substituted or unsubstituted phenyl and benzyl, said phenyl and benzyl substitutions are chosen from one or more:

i) halogen;

ii) C 1 -C 3 alkyl;

iii) C 1 -C 3 alkoxy;

iv) —CO 2 R 11 ; or

v) —NHCOR 12 ;

wherein R 11 and R 12 are each independently hydrogen, methyl, or ethyl.

25. The method according to claim 22 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by a carboxy unit having the formula —C(O)R 9 ; R 9 is chosen from methyl, methoxy, ethyl, and ethoxy.

26. The method according to claim 22 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by an amide unit having the formula —NHC(O)R 9 ; R 9 is chosen from methyl, methoxy, ethyl, ethoxy, tert-butyl, and tert-butoxy.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: AERPIO PHARMACEUTICALS, INC.
To: EYEPOINT PHARMACEUTICALS, INC.
Reel/Frame 057448/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2020
From: AERPIO THERAPEUTICS LLC
To: AERPIO PHARMACEUTICALS, INC.
Reel/Frame 052432/0789 →
CHANGE OF NAME Recorded Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049922/0273 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2012
From: AKEBIA THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 027796/0534 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2011
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS INC.
Reel/Frame 027445/0100 →
PATENT RELEASE Recorded Dec 23, 2011
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 027443/0164 →
SECURITY AGREEMENT Recorded Mar 30, 2011
From: WARNER CHILCOTT COMPANY LLC
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026064/0607 →